Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property protections in the U.S. and Japan, marking a pivotal step in the global commercialization strategy for LP-284.

Developed using Lantern Pharma’s innovative RADR(R) AI platform, LP-284 is currently undergoing Phase 1 clinical trials. The drug has also been granted Orphan Drug Designations for Mantle Cell Lymphoma (MCL) and High-Grade B-Cell Lymphoma (HGBL), underscoring its potential to address unmet medical needs in these areas. With a target market estimated at $4 billion globally, LP-284 represents a significant opportunity for Lantern Pharma to make a substantial impact in the oncology sector.

The rapid development timeline and cost efficiency of LP-284, facilitated by the RADR(R) AI platform, highlight Lantern Pharma’s ability to accelerate the drug discovery and development process. This achievement not only strengthens the company’s position in the competitive oncology drug market but also enhances its potential for strategic partnerships. The use of AI in drug development, as demonstrated by Lantern Pharma, offers a promising avenue for reducing costs and timelines, thereby bringing effective treatments to patients faster.

For more information on Lantern Pharma and its advancements in AI-driven oncology drug development, visit https://ibn.fm/Rx6Jq.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284.